Excessive fecal bile acid (BA) loss causes symptoms in a large proportion of people diagnosed with irritable bowel syndrome with diarrhea, a common functional bowel disorder. This BA diarrhea (BAD) results from increased hepatic synthesis of BAs, with impaired negative feedback regulation by the ileal hormone fibroblast growth factor 19 (FGF19). In this issue of the JCI, Zhao et al. investigated BA metabolism, including fecal BAs, serum BAs, and FGF19, in patients and controls. They identified associations between fecal bacterial BA metabolism and specific microbiota, especially Clostridium scindens. These findings have been tested in a mouse model using microbiota transplants and antibiotic treatment. This group of organisms has potential as a biomarker for BAD and to be a target for therapy.
Julian R.F. Walters, Julian R. Marchesi
Title and authors | Publication | Year |
---|---|---|
Pathophysiology and Clinical Management of Bile Acid Diarrhea
Marasco G, Cremon C, Barbaro MR, Falangone F, Montanari D, Capuani F, Mastel G, Stanghellini V, Barbara G |
Journal of Clinical Medicine | 2022 |
Dietary fiber-based regulation of bile salt hydrolase activity in the gut microbiota and its relevance to human disease.
Kastl A, Zong W, Gershuni VM, Friedman ES, Tanes C, Boateng A, Mitchell WJ, O'Connor K, Bittinger K, Terry NA, Bales C, Albenberg L, Wu GD |
Gut microbes | 2022 |
The Role of Bile Acids in Chronic Diarrhea
M Camilleri, P Vijayvargiya |
The American Journal of Gastroenterology | 2020 |
Longitudinal profiling of the gut microbiome in patients with psoriatic arthritis and ankylosing spondylitis: a multicentre, prospective, observational study
Miguens Blanco J, Borghese F, McHugh N, Kelleher P, Sengupta R, Marchesi JR, Abraham S |
BMC Rheumatology | 2020 |